Clinical trial
Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety…
NCT00141102 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00141102 |
|---|---|
| Title | Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis |
| Official title | Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events |
| Acronym | CONDOR |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Arthritis, Rheumatoid |
| Intervention type | Drug |
| Interventions | Celecoxib, Diclofenac + Omeprazole |
| Enrollment | 4,484 |
| Start date | Oct 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Sep 1, 2005 |
| Last update posted | Mar 3, 2021 |
| Countries | Belgium, Brazil, Canada, China, Colombia, Costa Rica, Croatia, Czechia, Ecuador, Estonia, France, Germany and 20 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: